Renaissance Capital logo

Evotec Priced, Nasdaq: EVO

Provides drug discovery solutions for the pharmaceutical industry.

Industry: Health Care

Latest Trade: $3.43 0.00 (0.0%)

First Day Return: +1.1%

Return from IPO: -84.2%

Industry: Health Care

We are an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Our mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. To that end, we have built a comprehensive suite of fully integrated, next generation technology platforms which we believe will transform the way new drugs are discovered. By leveraging the advanced capabilities of our integrated platforms, we are able to provide solutions to our partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes. We generate revenue primarily through three core collaboration routes: (1) by providing our drug discovery capabilities on a fee-for-service and FTE-rate basis; (2) by receiving milestones and royalties on assets; and (3) by creating value through equity ownership in emerging, highly innovative biotechnology companies and translational academic institutional projects. Contracts with our partners can include elements of one or more of our three core collaboration routes.
more less
IPO Data
IPO File Date 10/08/2021
Offer Price $21.75
Price Range $21.75 - $21.75
Offer Shares (mm) 20.0
Deal Size ($mm) $435
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/03/2021
Offer Price $21.75
Price Range $21.75 - $21.75
Offer Shares (mm) 20.0
Deal Size ($mm) $435
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Morgan Stanley
more
Company Data
Headquarters Hamburg, Germany
Founded 1993
Employees at IPO 3,900
Website www.evotec.com

Evotec (EVO) Performance